GENinCode (LSE:GENI) Cash-to-Debt : 8.45 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is GENinCode Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. GENinCode's cash to debt ratio for the quarter that ended in Dec. 2023 was 8.45.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, GENinCode could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for GENinCode's Cash-to-Debt or its related term are showing as below:

LSE:GENI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.26 Med: 27.54 Max: No Debt
Current: 8.45

During the past 5 years, GENinCode's highest Cash to Debt Ratio was No Debt. The lowest was 0.26. And the median was 27.54.

LSE:GENI's Cash-to-Debt is ranked better than
76.32% of 228 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.285 vs LSE:GENI: 8.45

GENinCode Cash-to-Debt Historical Data

The historical data trend for GENinCode's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

GENinCode Cash-to-Debt Chart

GENinCode Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

0.26

No Debt

27.54

8.45

GENinCode Semi-Annual Data
	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial			No Debt	No Debt	27.54	16.22	8.45

Competitive Comparison of GENinCode's Cash-to-Debt

For the Diagnostics & Research subindustry, GENinCode's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GENinCode's Cash-to-Debt Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, GENinCode's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where GENinCode's Cash-to-Debt falls into.

GENinCode Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

GENinCode's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2.526	/	(0.078	+	0.221)
	=	8.45

GENinCode's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2.526	/	(0.078	+	0.221)
	=	8.45

GENinCode (LSE:GENI) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

GENinCode Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of GENinCode's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

GENinCode (LSE:GENI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » GENinCode PLC (LSE:GENI) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Oxford Science Park, John Eccles House, Robert Robertson Avenue, Oxford, GBR, OX4 4GP

Website

https://www.genincode.com

GENinCode PLC is engaged in the genetic risk assessment, prediction, and prevention of cardiovascular diseases including coronary artery diseases such as angina and myocardial infarction (heart attack), stroke, heart failure, hypertension, and other vascular heart diseases. The company's current product portfolio comprises Cardio inCode, LiPID inCode, SuDD inCode, and Thrombo inCode. The company has only one reportable segment being sale of kits and provision of support services. The Geographic Markets of the group are Chile, France, Italy, Sweden, Mexico, Spain and United Kingdom.